Highlights
- Supriya Lifescience shares declined nearly 9% after a sharp rally to record highs.
- The stock continues to trade well above its 21-day SMA despite the correction.
- RSI remains above 70, indicating elevated momentum even after recent profit booking.
Overview
Supriya Lifescience (NSE: SUPRIYA) witnessed sharp volatility on June 2, with shares declining 8.94% to INR 958.40 after recently touching fresh highs above INR 1,000. The pullback follows an exceptional rally over the past few weeks that significantly re-rated the stock. Despite the decline, the broader trend remains positive, with the stock continuing to trade substantially above key moving averages.
Fundamental View
For the quarter ended March 2026, Supriya Lifescience reported standalone total income of INR 28,000.60 lakh. Profit before tax stood at INR 9,212.90 lakh, while net profit came in at INR 7,422.90 lakh. Earnings per share (EPS) was reported at INR 9.22.
The latest results reflected healthy profitability and earnings generation. The company's strong financial performance has been one of the key factors behind the sharp appreciation seen in the stock during recent months.
Technical View
Supriya Lifescience traded at INR 958.40 after witnessing a sharp corrective move from recent highs. Despite the decline, the stock remains significantly above its 21-day SMA of INR 757.97, indicating that the broader technical structure remains positive.
Recent price action suggests profit booking after an extended rally rather than a complete trend reversal. The stock had moved into overextended territory following its rapid climb above the INR 1,000 mark. The 14-day RSI stood at 71.89, remaining above the overbought threshold despite the latest correction, highlighting the strength of the preceding uptrend.
Momentum Indicator
The RSI reading of 71.89 indicates elevated momentum conditions. While the indicator has eased from recent peaks, it remains above the overbought zone, suggesting that volatility may continue in the near term.
Key Technical Levels
Based on the current price of INR 958.40, immediate support is placed near INR 910.48, representing approximately 5% below the current market price. A stronger support zone is located around INR 862.56, which is roughly 10% below current levels and may act as an important area if profit booking extends.
On the upside, the first resistance level is positioned near INR 1,006.32, approximately 5% above the current price. If bullish momentum resumes, the next resistance zone could emerge around INR 1,054.24, representing nearly 10% upside from current levels.
Risks to Watch
- Extended rallies often attract aggressive profit booking.
- High RSI readings may increase short-term volatility.
- ASM framework monitoring could affect trading activity.
- Failure to hold support levels may weaken sentiment.
Summary
Supriya Lifescience shares witnessed a sharp correction after an exceptional rally that pushed the stock to record highs. While short-term profit booking has emerged, the stock continues to trade well above its 21-day SMA and maintains a positive broader trend. Investors may watch whether the stock stabilizes near support zones as momentum remains elevated despite the recent decline.
FAQs
- Why did Supriya Lifescience shares fall despite strong results?
The decline appears linked to profit booking following a steep rally rather than deterioration in the company's earnings performance.
- What is the key support level for SUPRIYA?
Immediate support is near INR 910.48, while stronger support is located around INR 862.56.
- What does the RSI indicate for the stock?
An RSI of 71.89 suggests momentum remains elevated, although the stock is still in overbought territory.